J&J : FDA Approves TREMFYA For Adult Patients With Moderately To Severely Active Crohn's Disease
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to se
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief